Eli Lilly posts 54% revenue growth, raises guidance, and drives innovation in obesity and diabetes care. Read here for an ...

System Approach Gains Traction Among Employers Addressing Musculoskeletal Health Costs and Worker Productivity ...

Arrowhead boasts a diversified RNAi pipeline targeting liver, lung, muscle, CNS, and obesity. Read why I recommend buying and ...

Looking for cheap 400-hp muscle? Here are 10 used V8 cars that mix serious power with surprising affordability on the used ...

ADVANCED-2 (NCT05951179) is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive ...

Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...

Heavy debts rattle investors already twitchy about runaway AI spending Oracle has taken a wallop as tech stocks and bonds ...

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

Q3 2025 Management View CEO Sergio Traversa highlighted a "standout year" for Relmada, citing "excellent product development ...

Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relationsAdvanced mu ...

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceed ...

Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q ...